The economic and financial impact of demographics

Population ageing is one of the most disruptive trends of the twenty-first century: it is affecting nearly all sectors of the society, from labour market and productivity to savings and consumption behavior.

Highlights:

  • Ageing is a global phenomenon of unprecedented magnitude and speed. It will exacerbate the pressure on public welfare systems and can contribute to a higher political uncertainty.
  • Economically, ageing as well as the shrinking of the working population will likely lower growth and hence the neutral key rate while dissaving will lead to upside pressure on inflation.
  • On balance the demographic changes are expected to reduce real yields in the years to come. Equity sectors related to the ageing process will benefit, including Asset & wealth management.
  • The increasing importance of private provision will open up new opportunities for the insurance sector.
  • Investment behavior is expected to shift towards less risky, cash flow yielding assets.
  • EM will dominate future ageing-related investment opportunities.

Read the full publication below.

THE ECONOMIC AND FINANCIAL IMPACT OF DEMOGRAPHICS

RELATED INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.